Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis.

Background: The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the management glomerular/systemic autoimmune diseases with proteinuria in real-world clinical settings is unclear.

Methods: This is a retrospective, observational, international cohort study. Adult patients with biopsy-proven glomerular diseases were included.

Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy: A Validation Study.

Background And Objectives: Kidney biopsy is the current gold standard to diagnose membranous nephropathy. Approximately 70%-80% of patients with primary membranous nephropathy have circulating anti-phospholipase A2 receptor antibodies. We previously demonstrated that in proteinuric patients with preserved eGFR and absence of associated conditions ( autoimmunity, malignancy, infection, drugs, and paraproteinemia), a positive anti-phospholipase A2 receptor antibody test by ELISA and immunofluorescence assay confirms the diagnosis of membranous nephropathy noninvasively.